Browse by Author "Aranda, E."

Now showing items 1-5 of 5

Combination of KIR2DS4 and Fc gamma RII alpha polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

2019- Borrero-Palacios, A.; Cebrian, A.; del Pulgar, M. T. G.; Garcia-Carbonero, R.; Garcia-Alfonso, P.; [et al.]
Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer

2023- Bonilla, C.E.; Montenegro, P.; O'Connor, J.M.; Hernando-Requejo, O.; Aranda, E.; [et al.]
Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

2022- Fernández Montes, Ana; Élez, E.; Vivancos, A.; Martínez, N.; González, P.; [et al.]
Treatment patterns for metastatic colorectal cancer in Spain

2020- Aranda, E.; Polo, E.; Camps, C.; Carrato, A.; Diaz-Rubio, E.; [et al.]
Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials

2019- Benavides, M.; Díaz-Rubio, E.; Carrato, A.; Abad, A.; Guillén, C.; [et al.]